Anti-adam33 oligonucleotides and related methods
AssigneesUniversity of Massachusetts, University of Southampton
InventorsJonathan Watts, Hans Michael Haitchi, Hannah Pendergraff
Life of this patent
Estimating the term…
Abstract
The present disclosure provides antisense compounds, methods, and compositions for silencing ADAM33 mRNA. The present disclosure provides antisense compounds, methods, and compositions for the treatment, prevention, or amelioration of diseases, disorders, and conditions associated with ADAM33 in a subject in need thereof. Also contemplated are antisense compounds and methods for the preparation of a medicament for the treatment, prevention, or amelioration of a disease, disorder, or condition associated with ADAM33.
Claims22
1-97. (canceled)
A method of treating a disintegrin and metalloprotease domain-containing protein 33 (ADAM33)-related skin disease or cardiovascular disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a synthetic antisense oligonucleotide (ASO) having a target-recognition sequence that is sufficiently complementary to an ADAM33 transcript to direct cleavage of the ADAM33 transcript by RNase H.
101-105. (canceled)
Dependencies are inferred from the claim text.